Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Fibrosis

Explore clinical trials studying Pulmonary Fibrosis. Study availability and eligibility vary by location and protocol.

374 public trials 55 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Fibrosis trial results

Completed

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

NCT02802345

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Pulmonary Assoc of Stamford Stamford, Connecticut, United States
  • University of Florida College of Medicine Jacksonville, Florida, United States
  • University of Chicago Chicago, Illinois, United States
View all 85 locations
View Trial Details
Completed

Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry

NCT00540475

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • Milton S. Hershey Medical Center Hershey, Pennsylvania, United States
  • University of Pennsylvania Health System Philadelphia, Pennsylvania, United States
  • Temple University Philadelphia, Pennsylvania, United States
  • Dorothy P. & Richard P. Simmons Center for Interstitial Lung Disease Pittsburgh, Pennsylvania, United States
View Trial Details
Completed

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01872689

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • University Alabama At Birmingham Birmingham, Alabama, United States
  • Mayo Clinic- Scottsdale Scottsdale, Arizona, United States
  • Southern Arizona Veterans Administration Healthcare Systems Tucson, Arizona, United States
  • University of Arizona Tucson, Arizona, United States
View all 112 locations
View Trial Details
Completed

Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT02598193

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • David Geffen School of Medicine at UCLA;Division of Pulmonary & Critical Care/ Department of Medic Los Angeles, California, United States
  • Stanford University School of Medicine ; Pulmonary/Critical Care Medicine Stanford, California, United States
  • Sarasota Memorial Hospital Sarasota, Florida, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View all 38 locations
View Trial Details
Completed

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

NCT01979952

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • Western CT Medical Group, P.C. Danbury, Connecticut, United States
  • Clinical Research Center Sarasota Memorial Hosptial Sarasota, Florida, United States
  • Chest Medicine Clinical Services Skokie, Illinois, United States
  • Baptist Health Lexington Lexington, Kentucky, United States
View all 25 locations
View Trial Details
Completed

Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

NCT02579603

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • Western CT Medical Group, P.C. Danbury, Connecticut, United States
  • Tulane University Hospital and Clinic New Orleans, Louisiana, United States
  • Minnesota Lung Center Minneapolis, Minnesota, United States
  • The Lung Research Center, LLC Chesterfield, Missouri, United States
View all 23 locations
View Trial Details

Related conditions